<DOC>
	<DOCNO>NCT00274105</DOCNO>
	<brief_summary>The aim trial evaluate efficacy safety telmisartan 80 mg administer daily patient document coronary artery disease ( CAD ) probably cardiovascular risk profile concern amelioration structural alteration endothelial function . The primary objective trial evaluate efficacy particular regard percentage change atheroma volume femoral artery.The secondary objective evaluate change plaque size- assess intravascular ultrasound , increase Flow Dependent Dilation provoke intraarterial infusion three increase concentration Acetylcholine , change seat systolic blood pressure . Endothelial dysfunction primary event atherogenesis know cardiovascular risk factor associate endothelial dysfunction atherosclerotic vascular disease manifest clinically . Pivotal endothelial dysfunction disturbance function endothelium-derived nitric oxide ( NO ) . Recently , could show acute chronic angiotensin-1 receptor antagonism reverse endothelial dysfunction atherosclerosis . In experimental atherosclerosis , AT1 receptor blockade appear protective effect . Respective potential mechanism include prevention endothelial injury , augmentation NO activity , inhibition lipid peroxidation antiproliferative effect . These finding together recent data losartan improve endothelial function NO activity suggest AT1 receptor antagonism may also antiatherogenic patient atherosclerosis . Angiotensin II influence smooth muscle cell migration , hyperplasia , hypertrophy . Angiotensin II also enhance production local superoxide anion , inactivate nitric oxide . Inhibition reactions AT1-Blocker telmisartan may therefore interfere atherosclerotic plaque formation .</brief_summary>
	<brief_title>SAFE-CRP : Structural Alterations Function Endothelium Cardiovascular Risk Patients</brief_title>
	<detailed_description>Methodology : 2:1 randomise , double-blind placebo-controlled parallel-group design Planned/actual number subject : Enrolled : 30/33 , randomise : 30/22 , complete : 30/15 Duration treatment : 9 month : telmisartan ( 80 mg ) Placebo ( 80 mg ) Study Hypothesis : The trial design group comparison telmisartan 80 mg placebo , treatment group randomise 2:1 relation , investigate efficacy telmisartan structural alteration endothelial dysfunction measure percentage change baseline 36 week treatment atheroma volume femoral artery use IVUS . Secondary endpoint change baseline flow dependent dilatation acetylcholine challenge follow nitro-glycerin bolus , change total atheroma volume , percentage atheroma volume measure intravascular ultrasound ( IVUS ) infalmmatory parameter MCP-1 , CRP , ox LDL antibodies sPLA2 activity amount . In analysis covariance use baseline covariate endpoint investigate . If assumption normal distribution fulfil , nonparametric method apply ( Wilcoxon-Mann-Whitney test ) . Comparison ( ) : Placebo 80 mg</detailed_description>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Inclusion criterion : 1 . &gt; 35 year age 2 . History coronary artery disease ( CAD ) 3 . Ability provide write informed consent Exclusion criterion : 1 . Premenopausal woman ( last menstruation &lt; 1 year prior start screen visit ) : 1. surgically sterile ; and/or 2. nursing 3. childbearing potential NOT practise acceptable mean birth control , NOT plan continue use method throughout study NOT agree submit periodic pregnancy test participation study &gt; 3months duration . Acceptable method birth control include oral , implantable injectable contraceptive 2 . Diastolic blood pressure &gt; 110 mmHg systolic blood pressure &gt; 180 mmHg visit study ( runin randomise period ) 3 . Hepatic and/or renal dysfunction define follow laboratory parameter : 1 . SGPT ( ALT ) SGOT ( AST ) &gt; 2 time upper limit normal range 2 . Serum creatinine &gt; 2.3 mg/dL 4 . Bilateral renal artery stenosis , renal artery stenosis solitary kidney , patient postrenal transplant one kidney 5 . Clinically relevant hypokalaemia hyperkalaemia 6 . Uncorrected volume depletion 7 . Uncorrected sodium depletion 8 . Primary aldosteronism 9 . Hereditary fructose intolerance 10 . Biliary obstructive disorder 11 . Patients previously experience symptom characteristic angioedema treatment ACE inhibitor angiotensin II receptor antagonists 12 . History drug alcohol dependency within 6 month 13 . Chronic administration medication know affect blood pressure , except medication allow protocol 14 . Any investigational therapy within one month signing informed consent form 15 . Known hypersensitivity component formulation 16 . Any clinical condition , opinion principal investigator , would allow safe completion protocol safe administration telmisartan 17 . Stroke within last 6 month 18 . Myocardial infarction within last 30 day 19 . Cardiac surgery within last 3 month 20 . Hyperthyroidosis 21 . Hemodynamically relevant valvular disease 22 . Restrictive hypertrophic cardiomyopathy 23 . Unstable angina pectoris 24 . CAD indication bypass surgery .</criteria>
	<gender>All</gender>
	<minimum_age>36 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>